Update on Multiple Myeloma Clinical Trials with Proteasome Inhibition from the 55th ASH Annual Meeting

Summary: Please join Kenneth Anderson, MD, from the Dana-Farber Cancer Institute, as he presents an informative update on recent advances in the management of multiple myeloma. His discussion highlights findings presented at the American Society of Hematology (ASH) 55th annual conference in New Orleans, LA, where he reviews 1) new data for patients with newly-diagnosed multiple myeloma; 2) options for patients with relapsed and refractory disease; and 3) data on long-term survivors with multiple myeloma, those who have survived 10 or more years after their diagnosis. A special focus includes review of current and emergent novel therapies for multiple myeloma, and how they are reshaping outcomes for these patients. 0.25 CME credits.